ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: L04 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease

    Maaman Bashir1, Katherine Sherman 2, Sara K. Tedeschi 3 and Ann Rosenthal 1, 1Medical College of Wisconsin, Milwaukee, 2Milwaukee VAMC, Milwaukee, 3Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston

    Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
  • Abstract Number: 316 • 2019 ACR/ARP Annual Meeting

    Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA

    Liliya Gandrabur1, Woo Young Kim 1, Aditi Sen 1, Deana Nes 1, Julia Ash 1, Amy Wasserman 1 and Kirk Sperber 1, 1Westchester Medical Center, Valhalla, NY

    Background/Purpose: Evidence suggests that the tools used for cardiovascular disease (CVD) risk assessment in the general population underestimate the true risk when they are applied…
  • Abstract Number: 1344 • 2019 ACR/ARP Annual Meeting

    Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study

    Eric Toussirot1, Hubert Marotte 2, denis Mulleman 3, gregoire Cormier 4, fabienne Coury-Lucas 5, Philippe Gaudin 6, Emmanuelle Dernis 7, christine bonnet 8, richard damade 9, jean-luc Grauer 10, Tassadit Ait Abdesselam 11, caroline Karras 12, frederic Liote 13, Pascal Hilliquin 14, antoinette sacchi 15, Jean-Marie Berthelot 16, marc puyraveau 1 and gilles dumoulin 1, 1University Hospital, Besancon, France, 2University Hospital, St Etienne, France, 3University hospital, Tours, France, 4CHD Vendée, La Roche sur Yon, France, 5University Hospital, Lyon, France, 6Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 7Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 8University Hospital, Limoges, France, 9Centre Hospitalier, Chartres, France, 10Centre Hopsitalier, Montelimar, France, 11Centre Hospitalier, Meaux, France, 12Hôpital Saint Joseph, Marseille, France, 13AP-HP, Paris, France, 14Centre Hospitalier, Corbeil Essones, France, 15Centre Hospitalier, Mantes la Jolie, France, 16University Hospital, Nantes, France

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) diseases. Dyslipidemia is a known adverse reaction to tocilizumab (TCZ). TNFa blockade…
  • Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting

    Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis

    Jeffrey Curtis1, Fenglong Xie 2, Cynthia Crowson 3, Brent Mabey 4, Darl Flake 4, Richard Bamford 4, Cheryl Chin 4, Eric Sasso 5, Elena Hitraya 5, Alexander Gutin 4 and Jerry Lanchbury 4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3Mayo Clinic Rochester, Rochester, 4Myriad Genetics, Inc, South San Francisco, CA, 5Crescendo Bioscience, South San Francisco, CA

    Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…
  • Abstract Number: 337 • 2019 ACR/ARP Annual Meeting

    Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study

    Alka Mithal 1, Maanek Sehgal 2 and Gurkirpal Singh1, 1ICORE, Woodside, 2UCLA, Los Angeles

    Background/Purpose: Gout is a disorder of uric acid metabolism and often presents as acute severe joint pain. Previous work from our group suggests that all-cause…
  • Abstract Number: 1405 • 2019 ACR/ARP Annual Meeting

    Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab

    Lovisa Lyngfelt1, Malin Erlandsson 2, Karin Andersson 2, Sofia Silfverswärd 2 and Maria Bokarewa 2, 1Department of Rheumatology and Inflammation Research at Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Adipose tissue is an important player in cardiovascular (CV) morbidity. Thermogenic brown adipocytes, rich with uncoupling protein 1 (UCP1), increase metabolic and CV health.…
  • Abstract Number: 2410 • 2019 ACR/ARP Annual Meeting

    Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable

    Mohammad Atiquzzaman1, Mohammad Karim 2, Jacek Kopec 3, Hubert Wong 4, Mary De Vera 5 and Aslam Anis 2, 1Faculty of Pharmaceutical Sciences, University of British Columbia, Surrey, BC, Canada, 2School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: BMI is a well-known confounding factor in the association between osteoarthritis (OA) and cardiovascular diseases (CVD). However, BMI is not usually recorded in administrative…
  • Abstract Number: 345 • 2019 ACR/ARP Annual Meeting

    Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey

    Kyong-Hee Jung1, Seung Yun Lee 1, Won Park 1, Young Ju Suh 1, Mie Jin Lim 1, Seong-Ryul Kwon 1, Joo-Hyun Lee 2 and Young Bin Joo 3, 1Inha University Hospital, Incheon, Republic of Korea, 2Inje University Ilsan Paik Hospital, Goyang, Republic of Korea, 3St. Vincent’s Hospital, Seoul, Republic of Korea

    Background/Purpose: The cardiovascular risk of gout is already well known, and the debate over the cardiovascular risk of uric acid lower agents is currently hot.…
  • Abstract Number: 1626 • 2019 ACR/ARP Annual Meeting

    Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus

    Mario Cesar Ocampo Torres 1, Elizabeth Olivares-Martinez 2 and Juanita Romero-Diaz3, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico

    Background/Purpose: Background/purpose Premature atherosclerosis has been recognized as a major cause of morbidity and mortality in SLE patients. We aimed to determine 1) the incidence…
  • Abstract Number: 2456 • 2019 ACR/ARP Annual Meeting

    Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis

    Keith Colaco1, Vinod Chandran 2, Dafna Gladman 3 and Lihi Eder 4, 1University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, 2University Health Network, University of Toronto, Toronto, Canada, 3Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 4Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada

    Background/Purpose: Valuable information on cardiovascular disease outcomes can be obtained from large cohort studies. Such studies often rely on self-reported events, which are best validated…
  • Abstract Number: 346 • 2019 ACR/ARP Annual Meeting

    Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016

    Chio Yokose1, Na Lu 2, Michael Chen-Xu 3, Natalie McCormick 4, Michael Pillinger 5, Yuqing Zhang 1 and Hyon K. Choi 1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hosptial, Boston, MA, 3Capital and Coast District Health Board, Wellington, New Zealand, 4Massachusetts General Hospital and Harvard Medical School, Boston, MA, 5New York University School of Medicine, New York

    Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…
  • Abstract Number: 1851 • 2019 ACR/ARP Annual Meeting

    The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus

    S Sam Lim1, Gaobin Bao 1, Charles Helmick 2, Charmayne Dunlop-Thomas 3 and Cristina Drenkard 1, 1Emory University, Atlanta, GA, 2Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, 3Emory University, Atlanta, Georgia

    Background/Purpose: African Americans (AA) are more likely to experience psychosocial and environmental stressors and develop SLE than whites. Increasing frequency of racial discrimination is associated…
  • Abstract Number: 2515 • 2019 ACR/ARP Annual Meeting

    Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis

    Natalia Palmou-Fontana1, DAVID MARTINEZ-LOPEZ 2, ALFONSO CORRALES 3, Fernanda Genre 4, SUSANA ARMESTO 5, MARCOS GONZALEZ 6, PATRICIA VICENTE-GOMEZ 7, JAVIER GARCIA-FERNANDEZ 6, VIRGINIA PORTILLA- GONZALEZ 5, MONICA PEREZ-ANDRES 5, Mónica Calderón-Goercke 8, DIANA PRIETO- PENA 1, Ricardo Blanco 9, JOSE LUIS HERNANDEZ 10, MIGUEL ANGEL GONZALEZ-GAY 11 and Iván Ferraz-Amaro 12, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 3Universitary Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 4Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 5UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, 6UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, 7Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 8Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 9Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 10UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, 11UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, 12Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain

    Background/Purpose: Objectives. The addition of carotid ultrasound CU into composite cardiovascular risk (CVR) scores has been found useful in the identification of high CVR in…
  • Abstract Number: 373 • 2019 ACR/ARP Annual Meeting

    Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis

    Patrice Cacoub1, Catherine Chapelon Abric 2, Matthieu Resche-Rigon 3, David Saadoun 2, Anne Desbois 2 and Lucie Biard 3, 1AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, 2GHPS, Paris, France, 3Hôpital Saint Louis, Paris, France

    Background/Purpose: To identify prognostic factors and to assess the effects of immunosuppressive drugs on relapse risk in patients presenting with cardiac sarcoidosis (CS).Methods: From a…
  • Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting

    Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques

    George Karpouzas1, Sarah Ormseth 1, Elizabeth Hernandez 2 and Matthew Budoff 1, 1Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, 2Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA

    Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…
  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology